Interleukin-19 increases angiogenesis in ischemic hind limbs by direct effects on both endothelial cells and macrophage polarization

Journal of Molecular and Cellular Cardiology

Volumn 79, Issue , 2015, Pages 21-31

  Richards, James ^a   Gabunia, Khatuna ^a   Kelemen, Sheri E ^a   Kako, Farah ^a   Choi, Eric T ^a   Autieri, Michael V ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Endothelial cell; Hind limb ischemia; Interleukin 19; Macrophage polarization

Indexed keywords

CD68 ANTIGEN; CXCL1 CHEMOKINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 12; INTERLEUKIN 19; INTERLEUKIN 8; PHOSPHATE BUFFERED SALINE; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 19; SCATTER FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN A; IL19 PROTEIN, MOUSE; INTERLEUKIN 10; INTERLEUKIN 12P40;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTERY LIGATION; ARTICLE; BLOOD FLOW; CAPILLARY DENSITY; CAPILLARY ENDOTHELIAL CELL; CELL ACTIVATION; CELL POLARITY; CONTROLLED STUDY; FEMALE; FEMORAL ARTERY; HINDLIMB; HINDLIMB ISCHEMIA; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; LASER DOPPLER FLOWMETRY; LIMB ISCHEMIA; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPLEEN; WILD TYPE; ANIMAL; C57BL MOUSE; CAPILLARY; CYTOLOGY; DEFICIENCY; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; ISCHEMIA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; REPERFUSION INJURY; VASCULARIZATION;

ANIMALS; CAPILLARIES; CELL POLARITY; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HINDLIMB; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12 SUBUNIT P40; ISCHEMIA; MACROPHAGES; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; PHENOTYPE; REPERFUSION INJURY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84911365001     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.11.002     Document Type: Article

References (56)

1. Cines D.B., Pollak E.S., Buck C.A., Loscalzo J., Zimmerman G.A., McEver R.P., et al. Endothelial cells in physiology and pathophysiology of vascular disorders. Blood 1998, 91:3527-3561.
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
3. Shireman P.K. The chemokine system in arteriogenesis and hind limb ischemia. J Vasc Surg 2007, 45(Suppl. A):A48-A56.
4. Park C.C., Morel J.C., Amin M.A., Connors M.A., Harlow L.A., Koch A.E. Evidence of IL-18 as a novel angiogenic mediator. J Immunol 2001, 167:1644-1653.
5. Salven P., Hattori K., Heissig B., Rafii S. Interleukin-1 alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J 2002, 16:1471-1483.
6. Huang S., Mills L., Mian B., Tellez C., McCarty M., Yang X.D., et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 2002, 161:125-134.
7. Del Vecchio M., Bajetta E., Canova S., Lotze M.T., Wesa A., Parmiani G., et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007, 13:4677-4685.
8. Silvestre J.S., Mallat Z., Duriez M., Tamarat R., Bureau M.F., Scherman D., et al. Antiangiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hindlimb. Circ Res 2000, 87:448-452.
9. Walch L., Massade L., Dufilho M., Brunet A., Rendu F. Pro-atherogenic effect of interleukin-4 in endothelial cells: modulation of oxidative stress, nitric oxide and monocyte chemoattractant protein-1 expression. Atherosclerosis 2006, 187:285-291.
10. Haas C.S., Amin M.A., Allen B.B., Ruth J.H., Haines G.K., Woods J.M., et al. Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. Arthritis Rheum 2006, 54:2402-2414.
11. Lee Y.W., Eum S.Y., Chen K.C., Hennig B., Toborek M. Gene expression profile in interleukin-4-stimulated human vascular endothelial cells. Mol Med 2004, 10:19-27.
12. Nishimura Y., Nitto T., Inoue T., Node K. IL-13 attenuates vascular tube formation via JAK2-STAT6 pathway. Circ J 2008, 72:469-475.
13. Hsieh M.Y., Chen W.Y., Jiang M.J., Cheng B.C., Huang T.Y., Chang M.S. Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun 2006, 7:234-242.
14. Tritsaris K., Myren M., Ditlev S.B., Hübschmann M.V., van der Blom I., Hansen A.J., et al. IL-20 is an arteriogenic cytokine that remodels collateral networks and improves functions of ischemic hind limbs. Proc Natl Acad Sci U S A 2007, 104:15364-15369.
15. Heuzé-Vourc'h N., Liu M., Dalwadi H., Baratelli F.E., Zhu L., Goodglick L., et al. IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression. Biochem Biophys Res Commun 2005, 333:470-475.
16. Bréchot N., Gomez E., Bignon M., Khallou-Laschet J., Dussiot M., Cazes A., et al. Modulation of macrophage activation state protects tissue from necrosis during critical limb ischemia in thrombospondin-1-deficient mice. PLoS One 2008, 3:e3950.
17. Arnold L., Henry A., Poron F., Baba-Amer Y., van Rooijen N., Plonquet A., et al. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J Exp Med 2007, 204:1057-1069.
18. Gallagher G., Dickensheets H., Eskdale J., Izotova L.S., Mirochnitchenko O.V., Peat J.D., et al. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immun 2000, 1:442-450.
19. Gallagher G. Interleukin-19: multiple roles in immune regulation and disease. Cytokine Growth Factor Rev 2010, 21:345-352.
20. Sabat R., Wallace E., Endesfelder S., Wolk K. IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases. Expert Opin Ther Targets 2007, 5:601-612.
21. Oral H., Kotenko S., Yilmaz M., Mani O., Zumkehr J., Blaser K., et al. Regulation of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-20, IL-22, IL-24 and IL-26. Eur J Immunol 2006, 36:380-388.
22. Gallagher G., Eskdale E., Jordan W., Peat J., Campbell J., Boniotto M., et al. Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses. Int Immunopharmacol 2004, 4:615-626.
23. Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., Fisher P.B. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004, 22:929-979.
24. Jain S., Gabunia K., Kelemen S.E., Panetti T.S., Autieri M.V. The anti-inflammatory cytokine interleukin 19 is expressed by and angiogenic for human endothelial cells. Arterioscler Thromb Vasc Biol 2011, 31:167-175.
25. Scholz D., Ziegelhoeffer T., Helisch A., Wagner S., Friedrich C., Podzuweit T., et al. Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. J Mol Cell Cardiol 2002, 34:775-787.
26. Lee C.W., Stabile E., Kinnaird T., Shou M., Devaney J.M., Epstein S.E., et al. Temporal patterns of gene expression after acute hindlimb ischemia in mice: insights into the genomic program for collateral vessel development. J Am Coll Cardiol 2004, 43:474-482.
27. Ellison S., Gabunia K., Richards J.M., Kelemen S.E., England R.N., Rudic D., et al. IL-19 reduces ligation-mediated neointimal hyperplasia by reducing vascular smooth muscle cell activation. Am J Pathol 2014, 184:2134-2143.
28. Limbourg A., Korff T., Napp L.C., Schaper W., Drexler H., Limbourg F.P. Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia. Nat Protoc 2009, 4:1737-1746.
29. Cuneo A.A., Herrick D., Autieri M.V. IL-19 Reduces VSMC Activation by Regulation of mRNA Regulatory Factor HuR and Reduction of mRNA Stability. J Mol Cell Cardiol. 2010, 49:647-654.
30. Liekens S., De Clercq E., Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001, 61:253-270.
31. Paoni N.F., Peale F., Wang F., Errett-Baroncini C., Steinmetz H., Toy K., et al. Time course of skeletal muscle repair and gene expression following acute hind limb ischemia in mice. Physiol Genomics 2002, 11:263-272.
32. Couffinhal T., Silver M., Zheng L.P., Kearney M., Witzenbichler B., Isner J.M. Mouse model of angiogenesis. Am J Pathol 1998, 152:1667-1679.
33. Scholz D., Ziegelhoeffer T., Helisch A., Wagner S., Friedrich C., Podzuweit T., et al. J Mol contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. Cell Cardiol 2002, 34:775-787.
34. Nakamura Y., Morishita R., Nakamura S., Aoki M., Moriguchi A., Matsumoto K., et al. A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension 1996, 28:409-413.
35. Morishita R., Nakamura S., Hayashi S., Taniyama Y., Moriguchi A., Nagano T., et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 1999, 33:1379-1384. [996].
36. Taniyama Y., Morishita R., Aoki M., Nakagami H., Yamamoto K., Yamazaki K., et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther 2001, 8:181-189.
37. Tian Y., Sommerville L.J., Cuneo A., Kelemen S.E., Autieri M.V. Expression and suppressive effects of interleukin-19 on vascular smooth muscle cell proliferation, signaling, and development of intimal hyperplasia. Am J Pathol 2008, 173:901-909.
38. Dhawan P., Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol 2002, 72:9-18.
39. Zaja-Milatovic S1., Richmond A. CXC chemokines and their receptors: a case for a significant biological role in cutaneous wound healing. Histol Histopathol 2008, 23:1399-1407.
40. Matsuda A., Fukuda S., Matsumoto K., Saito H. Th1/Th2 cytokines reciprocally regulate in vitro pulmonary angiogenesis via CXC chemokine synthesis. Am J Respir Cell Mol Biol 2008, 38:168-175.
41. Svensson J., Jenmalm M.C., Matussek A., Geffers R., Berg G., Ernerudh J. Macrophages at the fetal-maternal interface express markers of alternative activation and are induced by M-CSF and IL-10. J Immunol 2011, 187:3671-3682.
42. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
43. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-686.
44. Lamagna C., Aurrand-Lions M., Imhof B.A. Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 2006, 80:705-713.
45. Ligresti G., Aplin A.C., Zorzi P., Morishita A., Nicosia R.F. Macrophage-derived tumor necrosis factor alpha is an early component of the molecular cascade leading to angiogenesis in response to aortic injury. Arterioscler Thromb Vasc Biol 2011, 31:1151-1159.
46. Jetten N., Donners M.M., Wagenaar A., Cleutjens J.P., van Rooijen N., de Winther M.P., et al. Local delivery of polarized macrophages improves reperfusion recovery in a mouse hind limb ischemia model. PLoS One 2013, 8(7):e68811.
47. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012, 122:787-795.
48. Mantovani A. Sica Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22:231-237.
49. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6:389-395.
50. McLaren J., Prentice A., Charnock-Jones D.S., Millican S.A., Müller K.H., Sharkey A.M., et al. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest 1996, 98:482-489.
51. Brown L.F., Detmar M., Claffey K., Nagy J.A., Feng D., Dvorak A.M., et al. EXS. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997, 79:233-269.
52. Voest E.E., Kenyon B.M., O'Reilly M.S., Truitt G., D'Amato R.J., Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995, 87:581-586.
53. Coughlin C.M., Salhany K.E., Gee M.S., LaTemple D.C., Kotenko S., Ma X., et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998, 9:25-34.
54. Du C., Sriram S. Mechanism of inhibition of LPS-induced IL-12p40 production by IL-10 and TGFbeta. J Leukoc Biol 1998, 64:92-97.
55. Duda D.G., Sunamura M., Lozonschi L., Kodama T., Egawa S., Matsumoto G., et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 2000, 60:1111-1116.
56. Strasly M., Cavallo F., Geuna M., Mitola S., Colombo M.P., Forni G., et al. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol 2001, 166:3890-3899.